CD8A and neoplasm: DEX activation of CD4 + and CD8 + T cells after activation of DEX induces more effective antitumor immune responses in vivo through exosomal CD80 and endogenous IL-2 [42], which can then be used for the development of therapeutic vaccines for tumor immunotherapy.